AD2C-Oncology (GPC3)
Hepatocellular Carcinoma (HCC)
PreclinicalActive
Key Facts
About Acepodia
Acepodia is pioneering a novel approach to cell therapy with its Antibody-Cell Conjugation (ACC) and Antibody-Dual-Drugs Conjugation (AD2C) platforms. Founded in 2017 and based in the San Francisco Bay Area, the company has advanced multiple programs into Phase 1 clinical trials for oncology and autoimmune indications. With a strong scientific foundation linked to Nobel laureate Carolyn Bertozzi, strategic partnerships with industry leaders like Pfizer, and a recent $100 million Series D financing, Acepodia is positioned as an emerging innovator in the next generation of cell-based immunotherapies.
View full company profileTherapeutic Areas
Other Hepatocellular Carcinoma (HCC) Drugs
| Drug | Company | Phase |
|---|---|---|
| ADI-PEG 20 (pegargiminase) | Polaris Pharma | Phase 2/3 |
| Fostroxacitabine bralpamide (MIV-818) | Medivir | Phase 2a |
| YntraDose | BetaGlue Therapeutics | Pre-clinical |
| seRNA 001 | SRTD biotech | Preclinical |
| Seravue® (Diagnostic Assay) | ImCare Biotech | Development |
| ZW251 | Zymeworks | Phase 1 |
| TTI-101 | Tvardi Therapeutics | Phase 1b/2 |